| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/30/2007 | EP1789029A2 Methods and compositions for the treatment of cell proliferation |
| 05/30/2007 | EP1496925A4 Use of interleukin-24 to treat ovarian cancer |
| 05/30/2007 | EP1492560A4 Use of interleukin-19 to treat cervical cancer |
| 05/30/2007 | EP1482858A4 Methods for aneurysm repair |
| 05/30/2007 | EP1458672B1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha(ppar) |
| 05/30/2007 | EP1373220B1 Benzimidazoles that are useful in treating sexual dysfunction |
| 05/30/2007 | EP1318814B1 Triazole compounds useful as protein kinase inhibitors |
| 05/30/2007 | EP1311663B1 Claudin polypeptides |
| 05/30/2007 | EP1292335B1 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
| 05/30/2007 | EP1278517B1 Methods for improving size and appearance of a wound |
| 05/30/2007 | EP1221973B1 CD40 antagonist for treating psoriasis |
| 05/30/2007 | EP1206274B1 Use of interleukin-18 inhibitors to inhibit tumor metastasis |
| 05/30/2007 | EP1171165B1 Intramyocardial injection of autologous bone marrow |
| 05/30/2007 | EP0914605B1 Molecular model for vla-4 inhibitors |
| 05/30/2007 | CN1972716A Combinations comprising antimuscarinic agents and beta-adrenergic agonists |
| 05/30/2007 | CN1972715A Therapeutic agent for diabetes mellitus containing insulin resistance improving agent |
| 05/30/2007 | CN1972708A Compositions for topical treatment |
| 05/30/2007 | CN1972686A Uses of selective cytokine inhibitory drugs in myelodysplastic syndromes |
| 05/30/2007 | CN1972684A Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension |
| 05/30/2007 | CN1972679A Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1-receptor antagonists |
| 05/30/2007 | CN1972678A Steroid intraocular implants having an extended sustained release for a period of greater than two months |
| 05/30/2007 | CN1972676A Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens |
| 05/30/2007 | CN1972672A Non-animal product-containing veterinary formulations |
| 05/30/2007 | CN1972665A Injectable depot compositions and uses thereof |
| 05/30/2007 | CN1970083A Solid pharmaceutical formulation of proton pump inhibitor |
| 05/30/2007 | CN1969874A Externally applied pharmaceutical composition of abafungin |
| 05/30/2007 | CN1969835A Carboxyl contained NSAIDS (nonsteroidal anti-inflammatory drugs) salt |
| 05/30/2007 | CN1969828A Anticancer sustained release injection containing mesenchyme hydrolytic agent |
| 05/30/2007 | CN1969827A Anti-solid tumor composition containing epothilone and mesenchyme hydrolytic agent |
| 05/30/2007 | CN1969826A Fluorouracil and its synergist carried sustained release agent |
| 05/30/2007 | CN1969825A Sustained release agent containing fluorouracil and synergist thereof |
| 05/30/2007 | CN1969824A Anticancer sustained release agent containing fluorouracil and synergist thereof |
| 05/30/2007 | CN1969823A Sustained release agent containing fluorouracil and synergist thereof |
| 05/30/2007 | CN1969821A Anticancer medicament and synergist simultaneously carrying anticancer sustained release agent |
| 05/30/2007 | CN1969820A Anticancer pharmaceutical composition |
| 05/30/2007 | CN1969818A Anticancer sustained release injection containing epothilone derivatives |
| 05/30/2007 | CN1969817A Anticancer composition |
| 05/30/2007 | CN1969816A Anticancer sustained release agent containing epothilone |
| 05/30/2007 | CN1318404C Aryl ureas as kinase inhibitors |
| 05/30/2007 | CN1318103C Medical products comprising a haemocompatible coating, production and use thereof |
| 05/30/2007 | CN1318093C Injections for eye tissue containing drug bound to polyethylene glycol |
| 05/30/2007 | CN1318092C Immunity treatment composition containing antibody-cytokine fusion protein mediated and angiogenesis inhibitor |
| 05/30/2007 | CN1318091C Use of biologically active HIV-1 Tat, fragments or derivatives thereof for preventing or therapeutic vaccination and/or treating other diseases |
| 05/30/2007 | CN1318086C Use of soluble CTLA4 molecule in preparation of medicine composition for treating rheumatic diseases |
| 05/30/2007 | CN1318031C Compositions containing benzoxazinone and nucleoside like materials |
| 05/30/2007 | CN1318030C Methods and compositions useful in enhancing oxygen delivery to cells |
| 05/30/2007 | CN1318027C GABA enhancers in the treatment of diseases relating to reduced neurosteroid activity |
| 05/29/2007 | US7225083 Determination antagonist, moderators; three-dimensional models |
| 05/29/2007 | US7223858 Truncated aggrecanase molecules |
| 05/29/2007 | US7223852 Nucleic acids encoding TRAIN-R: a cysteine rich member of the TNF-receptor family |
| 05/29/2007 | US7223839 Splice variants of the human H3 histamine receptor having deletions of portions of the N-terminal of the wild type H3 receptor; useful in methods for identifying agonists, inverse agonists or antagonists of histamine action at the H3 receptor; therapeutic and diagnostic agents; nervous system disorders |
| 05/29/2007 | US7223834 Assays and peptide substrate for determining aggrecan degrading metallo protease activity |
| 05/29/2007 | US7223794 For example, 2-{[(1S)-2-amino-1-phenylethyl]oxy}-4-chloro-5-fluorobenzonitrile; use in treatment or prophylaxis of inflammatory diseases and CNS diseases |
| 05/29/2007 | US7223790 Dimeric compounds and their use as anti-viral agents |
| 05/29/2007 | US7223757 Such as (S)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-{6-[4-(2-methoxy-ethyl)-piperazin-1-yl]-4-methyl-1H-benzimidazol-2-yl}-1H-pyridin-2-one bis hydrochloride; anticancer agents; antiproliferative agents |
| 05/29/2007 | US7223741 nucleic acids containing unmethylated cytosine-guanine (CpG) dinucleotides activate lymphocytes in a subject and redirect a subject's immune response from a Th2 to a Th1 |
| 05/29/2007 | US7223739 Adjuvanted genetic vaccines |
| 05/29/2007 | US7223738 Inhibitors of Akt activity |
| 05/29/2007 | US7223736 Composition for the prevention and treatment of cachexia |
| 05/29/2007 | US7223732 Polypeptides; wound healing agents, antiulcer agents |
| 05/29/2007 | US7223600 cell is contacted with a photosentistising agent, cell is irradiated with light to activate photosentisitising agent, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination |
| 05/29/2007 | US7223563 Nucleic acids; diagnosing and treating hypophosphatemic disorders; diagnosing tumor induced osteomalacia |
| 05/29/2007 | US7223554 Inhibitors of proteasomal activity for stimulating hair growth |
| 05/29/2007 | US7223434 Mixtures of alpha-linolenic acid, linoleic acid, soybean oil, sunflower oil, coconut oil and nucleotides selected from adenosine, cytidine, guanosine, uridine, inosine or thymidine, used as nutraceuticals for infants |
| 05/29/2007 | US7223413 Composition of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; heart can be better protected during arrest and recovery by using the potassium channel opener adenosine and the local anaesthetic lignocaine |
| 05/29/2007 | US7223399 administering the toxin directly to a blood vessel, especially following a cardiovascular procedure. |
| 05/29/2007 | US7223397 Administering an agent which upregulates the expression of a cellular target; administering a dose of an immunotoxin directed against the upregulated cellular target |
| 05/29/2007 | US7223381 Pressurised metered dose inhalers (MDI) |
| 05/29/2007 | CA2401718C Compositions and methods for treating hair loss using c16 - c20 aromatic tetrahydro prostaglandins |
| 05/29/2007 | CA2340052C Pharmaceutical compositions containing lipase inhibitors and chitosan |
| 05/29/2007 | CA2333375C Sublingual buccal effervescent |
| 05/29/2007 | CA2090612C Method of reversing local anesthesia and reagent system therefor |
| 05/24/2007 | WO2007058805A2 Compositions and methods for treating cns disorders |
| 05/24/2007 | WO2007058671A1 Novel uses of cells with prenatal patterns of gene expression |
| 05/24/2007 | WO2007058504A1 Novel compounds as agonist for ppar gamma and ppar alpha, method for preparation of the same, and pharmaceutical composition containing the same |
| 05/24/2007 | WO2007058392A1 Heterocyclic compound and medicinal application thereof |
| 05/24/2007 | WO2007058384A1 Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same |
| 05/24/2007 | WO2007058359A1 THERAPEUTIC AGENT FOR SKIN OR SKIN REPAIR-PROMOTING AGENT COMPRISING GHRELIN, DERIVATIVE THEREOF OR SUBSTANCE CAPABLE OF ACTING ON GHS-R1a AS ACTIVE INGREDIENT |
| 05/24/2007 | WO2007058336A1 SCREENING METHOD AND IDENTIFICATION METHOD FOR SUBSTANCE CAPABLE OF INHIBITING DEGRANULATION REACTION OR PROSTAGLANDIN D2 PRODUCTION IN MAST CELL THROUGH Rec168, AND THERAPEUTIC AGENT FOR INFLAMMATORY DISEASE COMPRISING THE SUBSTANCE |
| 05/24/2007 | WO2007058194A1 Inhibitor of cytotoxic t cell induction |
| 05/24/2007 | WO2007057714A2 Pharmaceutical compositions comprising methotrexate |
| 05/24/2007 | WO2007057440A2 Improved methods of using phosphoantigen for the treatment of cancer |
| 05/24/2007 | WO2007037133A9 Method for evaluation of compound capable of acting on plk3 |
| 05/24/2007 | WO2000009653A3 Method of inhibiting cathepsin k |
| 05/24/2007 | US20070117833 Pharmaceutical compositions |
| 05/24/2007 | US20070117825 Use of amide derivative of ge 2270 factor a3 for the treatment of acne |
| 05/24/2007 | US20070117807 Potassium channel modulators; cardiovascular disorders; antiarrhythmia agents; synthesis |
| 05/24/2007 | US20070117788 Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases |
| 05/24/2007 | US20070117165 Detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells |
| 05/24/2007 | US20070117162 Kidney-specific urate transporter and gene thereof |
| 05/24/2007 | US20070117160 Novel method of screening |
| 05/24/2007 | US20070117142 Regulation of novel human asparagine-hydroxylases |
| 05/24/2007 | US20070117098 'signalin' family of TGFbeta signal transduction proteins and uses related thereto |
| 05/24/2007 | US20070116694 Inhibitor of interaction of granzyme b with golgin-160 |
| 05/24/2007 | US20070116688 Methods of organ regeneration |
| 05/24/2007 | US20070116672 Treatment of rheumatic diseases |
| 05/24/2007 | DE102005055275A1 Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung Phosphate-free pharmaceutical composition and use thereof |
| 05/24/2007 | CA2630006A1 Skin repair accelerating therapeutic agent containing ghrelin and derivatives thereof or substance acting on ghs-r1a as active ingredient |
| 05/24/2007 | CA2629437A1 Pharmaceutical compositions comprising methotrexate |
| 05/24/2007 | CA2629312A1 Compositions and methods for treating cns disorders |